

# Non-Small Cell Lung Cancer Market Size to Exceed USD 3,390 Billion by 2030 | CAGR Of 10.4%

*Rise in prevalence of lung cancer occur in people who smoke and consume tobacco drive the growth of the global non small cell lung cancer market.*

PUNE, MAHARASHTRA, INDIA, March 1, 2023 /EINPresswire.com/ -- Non-small cell lung cancer is caused when the cells present in the body grow at an uncontrolled rate, leading to the formation of a tumor. NSCLC has different stages based on its progression. STAGE IV is the final stage of the disease, which is marked by the spreading of tumors into others parts of body. The management of NSCLC in patients requires the use of different treatments, such as immunotherapy, targeted therapy, and chemotherapy.



Allied Market Research has published a study report with the title [Non-Small Cell Lung Cancer Market](#) Size was Valued at USD 1,258 billion in 2020 and is Projected to Garner USD 3,390 billion by 2030, registering a CAGR of 10.4% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, major segments, value chains, competitive scenarios, and regional landscapes. This research offers valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.

Rise in prevalence of lung cancer occur in people who smoke and consume tobacco drive the growth of the global non small cell lung cancer market. However, high-cost expenditure in the treatment of non-small cell lung cancer and stringent government rules for product approval restrict the market growth. Moreover, widespread use of sneakers in numerous environments and a large consumer base including fitness & gym visitors, athletes, and rock climbers, present new opportunities in the coming years.

Global Small Cell Lung Cancer Market Report, Forecast to 2031

- F. Hoffmann-La Roche Ltd,
- Novartis AG,
- Pfizer Inc.,
- AstraZeneca,
- Eli Lilly and Company,
- Merck & Co., Inc.,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- Sanofi,
- Boehringer Ingelheim

Global Small Cell Lung Cancer Market Report, Forecast to 2031  
Key Players, Market Segments:

Based on type, the adenocarcinoma segment held the highest market share in 2021, accounting for nearly half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to rise in smoking on regular basis around the globe. However, the large cell carcinoma segment is projected to manifest the highest CAGR of 11.3% from 2022 to 2031, owing to the advancements in R&D activities.

Based on treatment type, the targeted therapy segment held the highest market share in 2021, accounting for more than half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to its potential to prevent the growth of malignant cells. However, the immunotherapy segment is projected to manifest the highest CAGR of 12.7% from 2022 to 2031, owing to constant investment in developing new products by the key players.

Based on distribution channel, the hospital pharmacy segment accounted for the largest share in 2021, contributing to more than two-thirds of the global non small cell lung cancer market, and is projected to maintain its lead position during the forecast period. This is owing to prevalence of non-small cell lung cancer diseases, such as adenocarcinoma and large cell carcinoma and increase in number of hospitalization of patients suffering with NSCLC. However, the online pharmacy segment is expected to portray the largest CAGR of 15.1% from 2022 to 2031, owing to constant focus of market players to establish their products on e-commerce sales channels along with increase in number of online platforms related to healthcare.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for around two-fifths of the global non small cell lung cancer market, and is likely to dominate the market during the forecast period, owing to the presence of key players, rising

government initiatives, well-developed healthcare infrastructure, and rising awareness about the innovations in healthcare sector. However, the Asia-Pacific region is expected to witness the fastest CAGR of 10.5% from 2022 to 2031, owing to the investments by the public and private market players in this field.

□□□□□□□□ □□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/666>

## By Region Outlook

- North America  
(U.S., Canada, Mexico)
- Europe  
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific  
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA  
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

## Top Trending Report:

- AT-Home Testing Market: <https://www.alliedmarketresearch.com/at-home-testing-market-A31866>
- Resuscitation Devices Market: <https://www.alliedmarketresearch.com/resuscitation-devices-market-A11454>
- 3D Cell Culture Market: <https://www.alliedmarketresearch.com/3d-cell-cultures-market>
- Molecular diagnostics market: <https://www.alliedmarketresearch.com/molecular-diagnostics-market>
- Digital PCR Market: <https://www.alliedmarketresearch.com/digital-polymerase-chain-reaction-market>
- Dental Equipment Market: <https://www.alliedmarketresearch.com/dental-equipment-market>

## Contact Details:

David Correa  
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022  
[help@alliedmarketresearch.com](mailto:help@alliedmarketresearch.com)

## About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide

business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

David Correa

Allied Analytics LLP

+ + +1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/619658239>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.